

Yangli Zhang,^{a,b,†} Zengqiang Gao,^{c,†} Zhenzhen Zhang,^a Miao Luo,^b Ailong Huang,^a Yuhui Dong^c and Deqiang Wang^{a,b,*}

^aKey Laboratory of Molecular Biology of Infectious Diseases, Chongqing Medical University, 1 Yixueyuan Road, Chongqing 400016, People's Republic of China,

^bDepartment of Laboratory Medicine, Chongqing Medical University, 1 Yixueyuan Road, Chongqing 400016, People's Republic of China, and ^cBeijing Synchrotron Radiation Facility, Institute of High Energy Physics, Chinese Academy of Sciences, 19B Yuquan Road, Beijing 100039, People's Republic of China

† These authors contributed equally to this work.

Correspondence e-mail: wangd@ustc.edu

Received 19 March 2012

Accepted 16 April 2012

Cloning, purification, crystallization and preliminary X-ray studies of human α_1 -microglobulin

α_1 -Microglobulin (α_1 m) is one of the phylogenetically most widespread lipocalins and is distributed in various organs and tissues, including liver, heart, eye, kidney, brain, lung, pancreas and skeletal muscle. α_1 m has been found to exert multifarious functions, including interacting with IgA, albumin and prothrombin, binding strongly to haem and exhibiting reductase activity. Nevertheless, little structural information is available regarding these functions of α_1 m. Since determination of three-dimensional structure is a powerful means of functional characterization, X-ray crystallography was used to accomplish this task. Here, the expression, purification, crystallization and preliminary crystallographic analysis of human α_1 m are reported. The crystal belonged to space group $P4_3$, with unit-cell parameters $a = b = 36.45$, $c = 112.68$ Å, and diffracted to a resolution of 2.0 Å. The crystals are most likely to contain one molecule in the asymmetric unit, with a V_M value of 1.63 Å³ Da⁻¹.

1. Introduction

The lipocalins, which are found in animals, plants and bacteria, are a superfamily of proteins consisting of 30–35 members (Flower, 1996; Åkerström *et al.*, 2000). The family has a well conserved three-dimensional structure, folding into a barrel consisting of eight anti-parallel β -strands with a closed end and an open end which provides a binding site for small hydrophobic ligands. Interestingly, lipocalins exert a surprisingly wide array of biological functions, but only a few members have been characterized, including the plant enzyme violaxanthin de-epoxygenase (Hieber *et al.*, 2000), insect bilin-binding protein (Huber *et al.*, 1987), and prostaglandin D-synthase (Urade & Hayaishi, 2000) and α_1 -microglobulin (α_1 m) from animals (Åkerström & Lögdberg, 2006).

α_1 m, also called protein HC, is one of the phylogenetically most widespread lipocalins (Tejler & Grubb, 1976). To date, it has been found in mammals, birds, fish and amphibians (Åkerström & Lögdberg, 2006). α_1 m is mainly synthesized in the liver, secreted into the blood and rapidly distributed to various organs and tissues, including liver, heart, eye, kidney, brain, lung, pancreas, skeletal muscle and blood. The lipocalin exists in a free form or as a component of protein complexes by binding to IgA, albumin and prothrombin (Berggård *et al.*, 1998; Allhorn *et al.*, 2002). The amino-acid sequence is highly conserved and the extent of its distribution indicates that α_1 m plays an important physiological function. Previous research has found that α_1 m can bind strongly to haem and that t- α_1 m, a truncated variant α_1 m that lacks the C-terminal tetrapeptide LIPR, can degrade haem with the help of Hb (Allhorn *et al.*, 2002). In addition, the secreted protein also exerts reductase and antioxidant activities by serving as a radical scavenger (Åkerström *et al.*, 2007). Nevertheless, little information is available about the active sites (or regions) and the mechanisms of the reductase and antioxidant activities of α_1 m. In order to further investigate the biochemical and physiological functions of α_1 m, we report the expression, purification, crystallization and preliminary X-ray crystallographic studies of human α_1 m. Structure determination will be pursued using experimental phasing methods. Determination of the three-dimensional structure of α_1 m will help in understanding how this widespread protein exerts its multitudinous functions.



Table 1

Data-collection statistics.

Values in parentheses are for the highest resolution shell.

Wavelength (Å)	1.0
Space group	$P4_3$
Unit-cell parameters (Å)	$a = b = 36.45, c = 112.68$
Resolution range (Å)	50–2.0 (2.07–2.00)
Total reflections	284280 (1946)
Unique reflections	9947
Completeness (%)	99.9 (98.9)
$\langle I/\sigma(I) \rangle$	16.7 (8.5)
Multiplicity	7.1 (7.3)
$R_{\text{merge}}^{\dagger}$	7.0 (35.8)

$\dagger R_{\text{merge}} = \frac{\sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle|}{\sum_{hkl} \sum_i I_i(hkl)}$, where $I_i(hkl)$ is the intensity of the i th measurement of an equivalent reflection with indices hkl .


2. Materials and methods

2.1. Cloning and expression

The gene encoding $\alpha_1\text{m}$ was amplified from human cDNA by PCR using primers ($\alpha_1\text{mFwd}$ and $\alpha_1\text{mRev}$) that contained *EcoRI* and *XhoI* restriction sites, respectively. Both the PCR products and the plasmid pET28a were digested with *EcoRI* and *XhoI* restriction enzymes. The ligation mixture was transformed into chemically competent *Escherichia coli* DH5 α cells and insertion was verified by PCR using T7 promoter and T7 terminator primers. The identity of the insert was further confirmed by DNA-sequence analysis. The final construct (pET28a- $\alpha_1\text{m}$) encodes $\alpha_1\text{m}$ protein with an N-terminal His tag. The recombinant expression vector was transformed into chemically competent *E. coli* BL21 (DE3) cells for expression. Cultures of bacteria carrying pET28a- $\alpha_1\text{m}$ were grown overnight in 20 ml LB medium supplemented with 50 mg l⁻¹ kanamycin. The bacteria were then used to inoculate 2.0 l LB medium and cultured at 310 K for about 4 h. The protein was induced by adding isopropyl β -D-1-thiogalactopyranoside (IPTG; 0.3 mM) when the OD_{600 nm} reached 0.4; the culture was allowed to grow at 293 K for a further 15 h before the cells were harvested by centrifugation.

2.2. Purification

The cells were resuspended in lysis buffer (20 mM Tris-HCl pH 8.0, 300 mM NaCl) and disrupted by sonication. The cell lysate was centrifuged at 15 000g for 30 min at 277 K and the cell debris was removed. The recombinant protein in the supernatant was applied onto a Ni²⁺-NTA (Qiagen) column pre-equilibrated with lysis buffer. Nonspecifically bound proteins were washed from the column with


Figure 1

A crystal of human $\alpha_1\text{m}$ as grown by the hanging-drop method. The average dimensions of the crystals were $0.1 \times 0.05 \times 0.05$ mm.


100 ml lysis buffer containing 50 mM imidazole. The recombinant protein was then eluted from the column with 20 ml elution buffer (20 mM Tris-HCl pH 8.0, 200 mM imidazole). The elution buffer was then loaded onto a HiTrap Q column (GE Healthcare) pre-equilibrated with 20 mM Tris-HCl pH 8.0 and the target protein was eluted with a linear gradient of 0–1000 mM NaCl in 20 mM Tris-HCl pH 8.0. For crystallization, fractions containing $\alpha_1\text{m}$ were concentrated and buffer-exchanged into the final buffer (5 mM Tris-HCl pH 8.0, 50 mM NaCl) using a Millipore Amicon concentrator with a 10 kDa cutoff membrane. The concentration of the purified protein was 10 mg ml⁻¹ and its purity was determined to be about 95% by SDS-PAGE.

2.3. Crystallization

Preliminary screening of crystallization conditions was performed by the hanging-drop vapour-diffusion method with Crystal Screen, Index and PEG/Ion kits (Hampton Research). The crystallization experiments consisted of 1.0 μ l protein solution mixed with 1.0 μ l reservoir solution and equilibrated against 400 μ l reservoir solution at 293 K. After 6 d, small crystals of $\alpha_1\text{m}$ were observed using a reservoir condition consisting of 20% (w/v) PEG 3350, 0.2 M ammonium citrate tribasic pH 7.0. Further optimization of the conditions using PEGs of different molecular weights at various concentrations gave good diffraction-quality crystals using 25–35% (w/v) PEG 3350 in the presence of 0.1 M HEPES pH 6.6–7.5. Crystals were obtained after 5 d equilibration against the crystallization solution and grew to full size ($0.05 \times 0.05 \times 0.1$ mm) in 15 d (Fig. 1).

2.4. Data collection and processing

Crystals were transferred to a reservoir solution adjusted to 20% (v/v) glycerol and immediately placed in a 100 K nitrogen-gas stream. X-ray diffraction data were collected from a single crystal using a MAR CCD detector on beamline U170 at SSRF (Fig. 2). The images were processed using *MOSFLM* (Leslie, 1992) and *SCALA* from the *CCP4* suite (Evans, 2006; Winn *et al.*, 2011). The final data-collection and processing statistics are given in Table 1.


Figure 2

X-ray diffraction image from a native human $\alpha_1\text{m}$ crystal recorded using a MAR CCD detector. The edge of the detector corresponds to a resolution of 2.0 Å.

3. Analysis and discussion of preliminary X-ray diffraction results

The overexpression method led to 20 mg pure protein being obtained from 3 l LB culture medium after purification by metal-affinity and ion-exchange chromatography. The purified $\alpha_1\text{m}$ was crystallized under PEG-containing conditions. Crystals suitable for X-ray diffraction were obtained after 15 d. A total of 284 280 measured reflections were merged into 9947 unique reflections with an R_{merge} of 7.0%. The merged data set was 99.9% complete to 2.0 Å resolution. The relevant data-collection statistics are given in Table 1. The $\alpha_1\text{m}$ crystal belonged to the tetragonal space group $P4_3$, with unit-cell parameters $a = b = 36.45$, $c = 112.68$ Å (Table 1). Based on the molecular weight of $\alpha_1\text{m}$ (about 23 kDa) and space group $P4_3$, solvent-content analysis indicated that one molecule could be accommodated per asymmetric unit, suggesting a V_M value (Matthews, 1968) of $1.63 \text{ \AA}^3 \text{ Da}^{-1}$ and a solvent content of 24.4%. Molecular replacement using *AMoRe* (Navaza, 2001), *Phaser* (McCoy *et al.*, 2005) and *MOLREP* (Vagin & Teplyakov, 2010) was carried out using the human prostaglandin D-synthase structure (PDB entry 3o19; Zhou *et al.*, 2010) as a search model. In order to solve the structure of $\alpha_1\text{m}$ by multiwavelength anomalous dispersion methods, a selenomethionyl derivative of $\alpha_1\text{m}$, which contains four methionine residues, is being prepared.

The authors would like to gratefully acknowledge SSRF beamline BL17U for crystal diffraction data collection. Financial support for this project was provided by research grants from the Chinese National Natural Science Foundation (grant Nos. 30600101, 30770481

and 30970563) and Natural Science Foundation of Chongqing (grant No. 2009BB5413) to DW.

References

- Åkerström, B., Flower, D. R. & Salier, J.-P. (2000). *Biochim. Biophys. Acta*, **1482**, 1–8.
- Åkerström, B. & Lögdberg, L. (2006). *Lipocalins*, edited by B. Åkerström, N. Borregaard, D. R. Flower & J.-P. Salier, pp. 110–120. Georgetown: Landes Bioscience.
- Åkerström, B., Maghzal, G. J., Winterbourn, C. C. & Kettle, A. J. (2007). *J. Biol. Chem.* **282**, 31493–31503.
- Allhorn, M., Berggård, T., Nordberg, J., Olsson, M. L. & Åkerström, B. (2002). *Blood*, **99**, 1894–1901.
- Berggård, T., Oury, T. D., Thogersen, I. B., Åkerström, B. & Enghild, J. J. (1998). *J. Histochem. Cytochem.* **46**, 887–894.
- Evans, P. (2006). *Acta Cryst.* **D62**, 72–82.
- Flower, D. R. (1996). *Biochem. J.* **318**, 1–14.
- Hieber, A. D., Bugos, R. C. & Yamamoto, H. Y. (2000). *Biochim. Biophys. Acta*, **1482**, 84–91.
- Huber, R., Schneider, M., Mayr, I., Müller, R., Deutzmann, R., Suter, F., Zuber, H., Falk, H. & Kayser, H. (1987). *J. Mol. Biol.* **198**, 499–513.
- Leslie, A. G. W. (1992). *Int CCP4/ESF-EACBM Newsl. Protein Crystallogr.* **26**.
- Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
- McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C. & Read, R. J. (2005). *Acta Cryst.* **D61**, 458–464.
- Navaza, J. (2001). *Acta Cryst.* **D57**, 1367–1372.
- Tejler, L. & Grubb, A. O. (1976). *Biochim. Biophys. Acta*, **439**, 82–94.
- Urade, Y. & Hayaishi, O. (2000). *Biochim. Biophys. Acta*, **1482**, 259–271.
- Vagin, A. & Teplyakov, A. (2010). *Acta Cryst.* **D66**, 22–25.
- Winn, M. D. *et al.* (2011). *Acta Cryst.* **D67**, 235–242.
- Zhou, Y., Shaw, N., Li, Y., Zhao, Y., Zhang, R. & Liu, Z.-J. (2010). *FASEB J.* **24**, 4668–4677.